Gallium-68 (Ga-68, 68Ga) is a positron-emitting radioisotope that is created from a 68Ge/68Ga generator. It has a half-life of 68 minutes, and is popular for its application as a radiopharmaceutical tracer used during PET scans. The introduction of PSMA-targeting tracers such as the PSMA-11, PSMA-617, and PSMA-I&T has increased the clinical utilization of 68Ga-radiopharmaceuticals for diagnostic imaging. The constantly growing applications of gallium-68 radiopharmaceuticals have gained increased attention in recent years. Gallium-68, when combined with lutetium-177 (Lu-177), allows diagnostic molecular imaging followed by the customized treatment based on the diagnostic scan. This method has proven to be more efficient for the treatment of neuroendocrine tumors (NETs) using the peptide receptor radionuclide therapy (PRRT). Studies suggest that more than 12,000 people in the U.S. are treated with neuroendocrine tumors each year. Thus, efforts are made to spread the information and data throughout the healthcare segments to enhance the results and studies. The growing awareness about NETs as well as advancements in nuclear medicine is expected to boost the gallium-68 market during the forecast period.
Presently, gallium-68 is most extensively utilized in the analysis of prostate cancer in the form of 68Ga, Ga-PSMA-11, respectively. The combination of Ga-68 and Lu-177 forms a theranostic pair, which is demonstrably effective for the treatment and diagnosis of prostate cancer, as the 68Ga/177Lu-radiolabelled tracers show a very similar biological behavior. Moreover, one of the market influencing applications of Ga-86-based radiopharmaceuticals is the labeling of human epidermal growth factor receptor family (HER2) and carcinoembryonic antigen (CEA). This is likely to improve the position of the global gallium-68 market. Furthermore, gallium-68 is a very helpful radionuclide for use in radiopharmacy. Moreover, it is popular in radiopharmaceuticals compared to other diagnostic isotopes. The usability and the commercial availability of generators simplified research and motivated developments with a view to a broad routine application.
The COVID-19 pandemic has had a profound impact on imaging practices across the country, which, in turn, influenced the decline in the demand for gallium-68. Stringent regulations for the global supply chain and trade of raw materials to limit the transmission of coronavirus are affecting the gallium-68 market in imaging applications. The globally available healthcare facilities have expanded their intake capacity for COVID-19 patients, which resulted in an unsafe ambiance for other imaging patients. Financial recessions usually tend to result in reduced healthcare investments; however, radiology practices have barely experienced any economic collapse that is concurrently intensified by the need to restrict the availability of imaging until the COVID-19 pandemic. The outpatient-heavy practices had the biggest impact on these changes, but all imaging volumes decreased. Nevertheless, various healthcare relief organizations are helping to provide several means of direct and indirect aid to healthcare providers and small businesses.
The actual impression that COVID-19 has had on the medical imaging industry with gallium-68 applications remains to be perceived, as hospitals and imaging facilities endeavor to figure out the post-COVID-19 era strategies, as nonessential imaging diagnosis and procedures were postponed. The professionals are deciding on new business models to restore the pending diagnosis and smoothly run the practices as before COVID-19. This is likely to create new opportunities for the gallium-68 market in the upcoming future. Moreover, the rapid progress in the COVID-19 vaccine distribution and upgrades in healthcare facilities ensure to open the market very shortly. The global gallium-68 market is expected to grow post-COVID-19 owing to several imagining and healthcare applications.
The applications of gallium-68 are emerging in nuclear medicine, due to its cyclotron-independency and availability via radionuclide generator. The detailed research and studies on gallium-68 resulted in the advancements of generator design facilitated research on new 68Ga-radiopharmaceuticals as well as the clinical use of the known. In addition, the gallium-68-labeled peptides have been identified as a unique class of radiopharmaceuticals dispensing fast target localization and blood clearance. The (68)Ga-Dototatoc, (8)Ga-Dotatate, (68)Ga-Dotanoc are the most popular radiopharmaceuticals currently in use for imaging and separating lesions of various somatostatin receptor subtypes, overexpressed in many neuroendocrine tumors.
Despite Ga-68 being available for more than three decades of research, its uses for clinical PET have recently emerged, and only now is it being applied to pre-clinical models of human disease. Moreover, other applications such as the Ga-67-citrate continue to be extensively used radiopharmaceutical for the clinical diagnosis of specific types of neoplasms, such as Hodgkin’s disease, lung cancer, non-Hodgkin’s lymphoma, malignant melanoma, and leukemia.
The Asia Pacific region is witnessing constant economic growth, improved healthcare facilities, rise in consumer awareness and incomes, and increase in the significance of nuclear medicine in numerous medical disciplines, including cardiology, oncology, and endocrinology. Moreover, there is an extended use with the potential to offer significant opportunities for gallium-68 in developing economies including China and India. Accordingly, major businesses and market players plan to invest and expand business in these countries. These players are adopting inorganic growth strategies to boost the global gallium-68 market during the forecast period. However, rise in access to healthcare and rapid introduction of advanced technological implementations in PET systems in North America are likely to result in the region’s dominance of the gallium-68 market.
On the contrary, the rising use of gallium-68 radiopharmaceuticals in the diagnosis of diseases related to cardiology, respiratory, and urology is anticipated to drive the gallium-68 market in Europe. Due to several such factors, the global gallium-68 market is projected to reach US$ 200 Mn by 2031, expanding at a CAGR of ~8% from 2021 to 2031.
Analysts’ Viewpoint
The rise in the prevalence of tumors and cancer has led to the growth in the demand for gallium-68, as radioisotopes in clinical PET imaging facilities are routines used. This is a major factor driving the demand for gallium-68. Gallium-68 has a growing influence in molecular imaging by positron emission tomography, owing to the easy availability from 68Ge/68Ga generator and cyclotrons, good radiation properties, and rich Ga3+ coordination chemistry. Thus, the rising utilization of gallium-68 based tracer in PET is expected to drive the global gallium-68 market. Furthermore, there is ongoing research activities by various businesses for several new applications of Ga-68, which can potentially create new and better opportunities for the global market. Additionally, newer 68Ga-labeled tracers are being examined for various therapeutic applications and in nuclear imaging. This is expected to propel the global gallium-68 market during the forecast period.
Gallium-68 Market – Segmentation
| Application |
|
| End User |
|
| Region |
|
Gallium-68 market was valued at ~US$ 100 Mn in 2020 and is projected to reach US$ 200 Mn by 2031
Gallium-68 market is projected to expand at a CAGR of ~8% from 2021 to 2031
Gallium-68 market is driven by growing awareness about NETs as well as advancements in nuclear medicine
The oncology segment accounted for a major share of the market, and the trend is anticipated to continue during the forecast period
Key players in the global gallium-68 market include Siemens Healthineers AG, ITM Isotopen Technologien München AG, Advanced Accelerator Applications (a Novartis AG Company), Telix Pharmaceuticals
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Gallium-68 Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Gallium-68 Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Health Care Industry Overview
5.2. Radioactive Material Transport Guidelines
5.3. Radiation Protection Guidelines
5.4. Installed PET Scanner Base Data, by Region
5.5. Number of PET/CT Scan, by Regions (2019)
5.6. FDA Approved Radiopharmaceuticals Products
5.7. PET Drug Workflow
5.8. Number of Radiotherapy Center: by Major Countries
5.9. Clinical Trials for Gallium-68 Radioisotope
5.10. COVID-19 Impact Analysis
6. Global Gallium-68 Market Analysis and Forecast, by Application
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Gallium-68 Market Value Forecast, by Application, 2017–2031
6.3.1. Hospitals
6.3.2. Diagnostic Centers
6.3.3. Others
6.4. Global Gallium-68 Market Attractiveness, by Application
7. Global Gallium-68 Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Gallium-68 Market Value Forecast, by Application, 2017–2031
7.3.1. Oncology
7.3.2. Cardiology
7.3.3. Neurology
7.3.4. Others
7.4. Global Gallium-68 Market Attractiveness, by Application
8. Global Gallium-68 Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Global Gallium-68 Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Global Gallium-68 Market Attractiveness, by Country/Region
9. North America Gallium-68 Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. North America Gallium-68 Market Value Forecast, by Application, 2017–2031
9.2.1. Hospitals
9.2.2. Diagnostic Centers
9.2.3. Others
9.3. North America Gallium-68 Market Value Forecast, by Application, 2017–2031
9.3.1. Oncology
9.3.2. Cardiology
9.3.3. Neurology
9.3.4. Others
9.4. North America Gallium-68 Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. North America Gallium-68 Market Attractiveness Analysis
9.5.1. By Application
9.5.2. By Application
9.5.3. By Country
10. Europe Gallium-68 Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Europe Gallium-68 Market Value Forecast, by Application, 2017–2031
10.2.1. Hospitals
10.2.2. Diagnostic Centers
10.2.3. Others
10.3. Europe Gallium-68 Market Value Forecast, by Application, 2017–2031
10.3.1. Oncology
10.3.2. Cardiology
10.3.3. Neurology
10.3.4. Others
10.4. Europe Gallium-68 Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Europe Gallium-68 Market Attractiveness Analysis
10.5.1. By Application
10.5.2. By Application
10.5.3. By Country/Sub-region
11. Asia Pacific Gallium-68 Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Asia Pacific Gallium-68 Market Value Forecast, by Application, 2017–2031
11.2.1. Hospitals
11.2.2. Diagnostic Centers
11.2.3. Others
11.3. Asia Pacific Gallium-68 Market Value Forecast, by Application, 2017–2031
11.3.1. Oncology
11.3.2. Cardiology
11.3.3. Neurology
11.3.4. Others
11.4. Asia Pacific Gallium-68 Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Gallium-68 Market Attractiveness Analysis
11.5.1. By Application
11.5.2. By Application
11.5.3. By Country/Sub-region
12. Latin America Gallium-68 Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Latin America Gallium-68 Market Value Forecast, by Application, 2017–2031
12.2.1. Hospitals
12.2.2. Diagnostic Centers
12.2.3. Others
12.3. Latin America Gallium-68 Market Value Forecast, by Application, 2017–2031
12.3.1. Oncology
12.3.2. Cardiology
12.3.3. Neurology
12.3.4. Others
12.4. Latin America Gallium-68 Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Gallium-68 Market Attractiveness Analysis
12.5.1. By Application
12.5.2. By Application
12.5.3. By Country/Sub-region
13. Middle East & Africa Gallium-68 Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Middle East & Africa Gallium-68 Market Value Forecast, by Application, 2017–2031
13.2.1. Hospitals
13.2.2. Diagnostic Centers
13.2.3. Others
13.3. Middle East & Africa Gallium-68 Market Value Forecast, by Application, 2017–2031
13.3.1. Oncology
13.3.2. Cardiology
13.3.3. Neurology
13.3.4. Others
13.4. Middle East & Africa Gallium-68 Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Middle East & Africa Gallium-68 Market Attractiveness Analysis
13.5.1. By Application
13.5.2. By Application
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Company Profiles
14.1.1. Siemens Healthineers AG
14.1.1.1. Company Overview
14.1.1.2. Company Financials
14.1.1.3. Growth Strategies
14.1.1.4. SWOT Analysis
14.1.2. ITM Isotopen Technologien München AG
14.1.2.1. Company Overview
14.1.2.2. Company Financials
14.1.2.3. Growth Strategies
14.1.2.4. SWOT Analysis
14.1.3. Advanced Accelerator Applications (a Novartis AG Company)
14.1.3.1. Company Overview
14.1.3.2. Company Financials
14.1.3.3. Growth Strategies
14.1.3.4. SWOT Analysis
14.1.4. Telix Pharmaceuticals
14.1.4.1. Company Overview
14.1.4.2. Company Financials
14.1.4.3. Growth Strategies
14.1.4.4. SWOT Analysis
List of Tables
Table 1: Health Care Industry Overview
Table 2: North America Installed Base
Table 3: Europe Installed Base
Table 4: Europe Installed Base
Table 5: Asia –Pacific Installed Base
Table 6: ROW Installed Base
Table 7: Number of PET/CT Scan by Continent
Table 8: Number of PET/CT Scan Performed in Asia
Table 9: Number of PET/CT Scan Performed in Eastern Europe and Northern Asia
Table 10: Number of PET/CT Scan Performed in Latin America & Caribbean
Table 11: Number of PET/CT Scan Performed in Middle East
Table 12: Number of PET/CT Scan Performed in Africa
Table 13: Number of PET/CT Scan Performed in High-income Countries (2018)
Table 14: FDA Approved Radiopharmaceuticals Products
Table 15: FDA Approved Radiopharmaceuticals Products
Table 16: FDA Approved Radiopharmaceuticals Products
Table 17: Number of Radiotherapy Centers, by Country
Table 18: Clinical trials involving the use of 68Ga radiopharmaceutical
Table 19: Clinical trials involving the use of 68Ga radiopharmaceutical
Table 20: Clinical trials involving the use of 68Ga radiopharmaceutical
Table 21: Clinical trials involving the use of 68Ga radiopharmaceutical
Table 22: Clinical trials involving the use of 68Ga radiopharmaceutical
Table 23: Clinical trials involving the use of 68Ga radiopharmaceutical
Table 24: Clinical trials involving the use of 68Ga radiopharmaceutical
Table 25: Clinical trials involving the use of 68Ga radiopharmaceutical
Table 26: Clinical trials involving the use of 68Ga radiopharmaceutical
Table 27: Clinical trials involving the use of 68Ga radiopharmaceutical
Table 28: Clinical trials involving the use of 68Ga radiopharmaceutical
Table 29: Clinical trials involving the use of 68Ga radiopharmaceutical
Table 30: Clinical trials involving the use of 68Ga radiopharmaceutical
Table 31: Clinical trials involving the use of 68Ga radiopharmaceutical
Table 32: Clinical trials involving the use of 68Ga radiopharmaceutical
Table 33: Global Gallium-68 Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 34: Global Gallium-68 Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 35: Global Gallium-68 Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 36: North America Gallium-68 Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 37: North America Gallium-68 Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 38: North America Gallium-68 Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 39: Europe Gallium-68 Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 40: Europe Gallium-68 Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 41: Europe Gallium-68 Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 42: Asia Pacific Gallium-68 Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 43: Asia Pacific Gallium-68 Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 44: Asia Pacific Gallium-68 Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 45: Latin America Gallium-68 Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 46: Latin America Gallium-68 Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 47: Latin America Gallium-68 Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 48: Middle East & Africa Gallium-68 Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 49: Middle East & Africa Gallium-68 Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 50: Middle East & Africa Gallium-68 Market Value (US$ Mn) Forecast, by Application, 2017–2031
List of Figure
Figure 01: Global Gallium-68 Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 02: Global Gallium-68 Market Value Share, by Region, 2020
Figure 03: PET Drug Workflow
Figure 04: Global Gallium-68 Market Value Share Analysis, by End-user, 2020 and 2031
Figure 05: Global Gallium-68 Market Value (US$ Mn), by Hospitals, 2017–2031
Figure 06: Global Gallium-68 Market Value (US$ Mn), by Diagnostic Centers, 2017–2031
Figure 07: Global Gallium-68 Market Value (US$ Mn), by Others, 2017–2031
Figure 08: Global Gallium-68 Market Attractive Analysis, by End-user, (2021-2031)
Figure 09: Global Gallium-68 Market Value Share Analysis, by Application, 2020 and 2031
Figure 10: Global Gallium-68 Market Attractiveness Analysis, by Application, 2021–2031
Figure 11: Global Gallium-68 Market Value (US$ Mn), by Oncology, 2017–2031
Figure 12: Global Gallium-68 Market Value (US$ Mn), by Cardiology , 2017–2031
Figure 13: Global Gallium-68 Market Value (US$ Mn), by Neurology, 2017–2031
Figure 14: Global Gallium-68 Market Value (US$ Mn), by Others, 2017–2031
Figure 15: Global Gallium-68 Market Value Share Analysis, by Region, 2020 and 2031
Figure 16: Global Gallium-68 Market Attractiveness Analysis, by Region, 2021–2031
Figure 17: North America Gallium-68 Market Value (US$ Mn) Forecast, 2017–2031
Figure 18: North America Gallium-68 Market Value Share Analysis, by Country, 2020 and 2031
Figure 19: North America Gallium-68 Market Attractiveness Analysis, by Country, 2021–2031
Figure 20: North America Gallium-68 Market Value Share Analysis, by End-user, 2020 and 2031
Figure 21: North America Gallium-68 Market Attractiveness Analysis, by End-user, 2021–2031
Figure 22: North America Gallium-68 Market Value Share Analysis, by Application, 2020 and 2031
Figure 23: North America Gallium-68 Market Attractiveness Analysis, by Application, 2021–2031
Figure 24: Europe Gallium-68 Market Value (US$ Mn) Forecast, 2017–2031
Figure 25: Europe Gallium-68 Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 26: Europe Gallium-68 Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 27: Europe Gallium-68 Market Value Share Analysis, by End-user, 2020 and 2031
Figure 28: Europe Gallium-68 Market Attractiveness Analysis, by End-user, 2021–2031
Figure 29: Europe Gallium-68 Market Value Share Analysis, by Application, 2020 and 2031
Figure 30: Europe Gallium-68 Market Attractiveness Analysis, by Application, 2021–2031
Figure 31: Asia Pacific Gallium-68 Market Value (US$ Mn) Forecast, 2017–2031
Figure 32: Asia Pacific Gallium-68 Market Value Share Analysis, by Country, 2020 and 2031
Figure 33: Asia Pacific Gallium-68 Market Attractiveness Analysis, by Country, 2021–2031
Figure 34: Asia Pacific Gallium-68 Market Value Share Analysis, by End-user, 2020 and 2031
Figure 35: Asia Pacific Gallium-68 Market Attractiveness Analysis, by End-user, 2021–2031
Figure 36: Asia Pacific Gallium-68 Market Value Share Analysis, by Application, 2020 and 2031
Figure 37: Asia Pacific Gallium-68 Market Attractiveness Analysis, by Application, 2021–2031
Figure 38: Latin America Gallium-68 Market Value (US$ Mn) Forecast, 2017–2031
Figure 39: Latin America Gallium-68 Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 40: Latin America Gallium-68 Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 41: Latin America Gallium-68 Market Value Share Analysis, by End-user, 2020 and 2031
Figure 42: Latin America Gallium-68 Market Attractiveness Analysis, by End-user, 2021–2031
Figure 43: Latin America Gallium-68 Market Value Share Analysis, by Application, 2020 and 2031
Figure 44: Latin America Gallium-68 Market Attractiveness Analysis, by Application, 2021–2031
Figure 45: Middle East & Africa Gallium-68 Market Value (US$ Mn) Forecast, 2017–2031
Figure 46: Middle East & Africa Gallium-68 Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 47: Middle East & Africa Gallium-68 Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 48: Middle East & Africa Gallium-68 Market Value Share Analysis, by End-user, 2020 and 2031
Figure 49: Middle East & Africa Gallium-68 Market Attractiveness Analysis, by End-user, 2021–2031
Figure 50: Middle East & Africa Gallium-68 Market Value Share Analysis, by Application, 2020 and 2031
Figure 51: Middle East & Africa Gallium-68 Market Attractiveness Analysis, by Application, 2021–2031
Figure 52: Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020
Figure 53: Breakdown of Net Sales (%), by Region, 2020
Figure 54: R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2020
Figure 55: Breakdown of Net Sales (%), by Business Segment, 2020
Figure 56: Revenue (US$ Thousand) and Y-o-Y Growth (%), 2018–2020
Figure 57: R&D Expenses (US$ Thousands) and Y-o-Y Growth (%), 2017–2020
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Gallium-68 Market
